[Allogenic bone marrow grafts (author's transl)]

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Bone marrow transplantation (BMT) is a critical therapy for severe aplastic anemia and chemotherapy-refractory acute leukemia.
• Successful BMT relies on identifying a human leukocyte antigen (HLA)-matched sibling donor.
• ABO compatibility is not a prerequisite for BMT.

Purpose of the Study:

• To outline the therapeutic approach and outcomes of bone marrow transplantation for severe aplastic anemia and acute leukemia.
• To detail the conditioning regimen and associated survival rates.
• To identify common immunologic complications following BMT.

Main Methods:

• Patients with severe aplastic anemia or acute leukemia received high-dose cyclophosphamide, with or without 1,000 rads total body irradiation, as a conditioning regimen.
• Human leukocyte antigen (HLA) matching was the primary criterion for donor selection.
• Survival rates and complications were monitored post-transplantation.

Main Results:

• Two-year survival rates were 17% for acute leukemia and 40% for aplastic anemia.
• The conditioning regimen involved high-dose cyclophosphamide, optionally combined with total body irradiation.
• Immunologic complications, including rejection, graft-versus-host disease, and immune deficiency, were observed.

Conclusions:

• Bone marrow transplantation is a feasible, albeit complex, treatment for specific hematologic conditions.
• Patient survival is significantly influenced by the underlying disease (aplastic anemia vs. acute leukemia).
• Management of post-transplant immunologic complications is essential for improving patient outcomes.